Seguridad Inclisirán [1]
Referencias
1. Khan, S. A., Naz, A., Qamar Masood, M., & Shah, R. (2020). Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. The American journal of cardiology, 134, 69–73. https://doi.org/10.1016/j.amjcard.2020.08.018 [2]
2. Lappin, J. and Llano, A. (2021), Inclisiran. Pract Diab, 38: 41-43. https://doi.org/10.1002/pdi.2333 [3]
3. Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P., Kastelein, J., & ORION-10 and ORION-11 Investigators (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England journal of medicine, 382(16), 1507–1519. https://doi.org/10.1056/NEJMoa1912387 [4]
4. Wang, Y., Wang, J., & Wang, S. (2018). Comparative Eectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 18(4), 271–282. https://doi.org/10.1007/s40256-018-0270-7 [5]
CC47368/67JLSDOYFPSDU